NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VR
Post# of 26
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), alongside research arm Cannevert Therapeutics Ltd., this morning announced that it is in the process of obtaining a fairness opinion from Davidson & Company LLP of Vancouver, Canada, regarding Veritas’ planned acquisition of the remaining 20 percent of Cannevert in the first quarter of 2018. Per the update, a fairness opinion is defined as “any written communication containing a conclusion as to the fairness of a proposed transaction to security holders, from a financial point of view.” Davidson & Company is expected to perform this process over the next three weeks, with a final report being prepared for the first week of March. “We are very close to taking over Cannevert,” Dr. Lui Franciosi, CEO of Veritas, stated in the news release. “Having a reputable accounting firm such as Davidson & Company will give Veritas a solid opinion on what they think Cannevert is worth after two years of extensive cannabis research.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer